Viking Therapeutics Inc. (VKTX)
Viking Therapeutics: Great Clinical Results Do Not Guarantee Commercialization Success
VKTX's obesity therapy candidate, VK2735, demonstrates accelerated weight loss results compared to Wegovy/ Mounjaro and the next-gen candidates, including CagriSema/ Zepbound/ Retatrutide. This explains why the stock is trading at a notable premium compared to its historical means and biotech sector, offering interested investors with a minimal margin of safety. VKTX remains a pre-revenue biotech company with uncertain means to bring the product to mass-market global commercialization upon the supposed US FDA/ the EU EC approval.
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
Is Viking Therapeutics a Millionaire-Maker?
Viking Therapeutics has a promising pipeline featuring several experimental drugs. The indications the company is targeting represent huge potential markets.
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
Viking Therapeutics, Inc. (VKTX) reachead $50.12 at the closing of the latest trading day, reflecting a +0.56% change compared to its last close.
Is Viking Therapeutics the Best Biotech Stock for You?
Viking Therapeutics' shares have skyrocketed this year. The biotech owes its performance to its two leading assets.
Is Viking Therapeutics Stock Running Out of Steam?
Viking's share price has been tumbling in recent months, and trading volumes are also down significantly. The stock could see an uptick in volume later this month once it posts its latest earnings numbers.
Viking Therapeutics: Potential Winner In Competitive Obesity Drug Race
Eli Lilly and Novo Nordisk dominate a weight loss drug sector heading towards a competitive race, but the market opportunity could reach over $100 billion. Viking Therapeutics, Inc. shows promising results with VK2735, potentially outperforming competitors in weight loss trials. The stock is an attractive investment with the potential for a premium buyout and consensus analyst price targets over 100% higher.
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
Viking Therapeutics stock is flying high thanks to its two leading pipeline candidates. But the biotech doesn't have any expected major catalysts to jolt its price by year-end.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.
The Best Biotech Stock to Invest $1,000 in Right Now
Viking Therapeutics has a few promising drug programs near maturity. It will have to ward off tough competitors to succeed.
